Clinical trials: Anticoagulant Drugs
Venous Thromboembolism (VTE), Cancer
Vortosiran for VTE Prevention
Blood clots remain a serious cause of illness and death. Long-term treatment and prevention of these clots with blood thinners is often limited by bleeding risk, drug interactions, and daily dosing, leading many patients to stop…
- Conditions
- Venous Thromboembolism (VTE), Cancer, Pulmonary Embolism (Diagnosis)
- Trial name
- NCT07850453
- Testing
- Vortosiran
- Where
- 30 sites in Bulgaria, France and 2 more
- Volunteers
- 150 people
- Sponsor
- Ribocure Pharmaceuticals AB
Hemorrhage, Thrombosis
Anticoagulant Therapy During Pacemaker Implantation
There are no established guidelines regarding interruption of warfarin anticoagulant therapy prior to surgical implantation of cardiac pacemakers.
- Conditions
- Hemorrhage, Thrombosis, Embolism
- Trial name
- FINPAC (NCT00479362)
- Testing
- Warfarin, Aspirin, Permanent pacemaker
- Where
- Finland
- Volunteers
- 447 people
- Sponsor
- University of Turku
Whole Blood Donation and Leukoreduction
Clinical Investigation to Evaluate the Hemanext® Oxygen Reduction System - Pivotal Trial
The primary goal of Hemanext. is to improve red cell storage through novel storage methods. Based on our review of the pertinent literature, there is substantial evidence suggesting that prolonged exposure to oxygen during…
- Trial name
- NCT03301779
- Testing
- Hemanext Red Blood Cell Processing System
- Where
- 3 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Hemanext
Atrial Fibrillation, Frailty
Prospective Monitoring of Non-Vitamin K Oral Anticoagulants in Older Adults With Atrial Fibrillation and Frailty
The objective of this study is to establish a near-real-time prospective monitoring program in Medicare, Optum and MarketScan Research data to evaluate the benefit of new cardiovascular disease (CVD) drugs for older adults with…
- Conditions
- Atrial Fibrillation, Frailty, Anticoagulant-induced Bleeding, Stroke
- Trial name
- NCT04878497
- Testing
- Warfarin, Dabigatran, Rivaroxaban
- Where
- United States
- Volunteers
- 1,000,000 people
- Sponsor
- Brigham and Women's Hospital
Atrial Fibrillation
Adherence to New Oral Anticoagulation Therapy in Turkey
This study will compose a national database of drug adherence and investigate the factors that affect drug adherence in patients taking new oral anticoagulation therapy in Turkish Population.
- Trial name
- NOAC-TR (NCT02480920)
- Where
- Turkey (Türkiye)
- Volunteers
- 2,738 people
- Sponsor
- Cardiovascular Academy Society, Turkey
Atrial Fibrillation, Medication Adherence
Use of Electronic Personal Health Records to Improve Medication Adherence
The purpose of this pilot study is to examine the use of a personal health record to improve medication adherence among patients with non-valvular atrial fibrillation taking dabigatran for primary prevention of embolic stroke.
- Trial name
- NCT03018197
- Testing
- Medication Education
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Parkview Health
Atrial Fibrillation, Medication Adherence
Adherence and Coagulation Assays in Dabigatran-treated Patients With Atrial Fibrillation
In patients with non-valvular atrial fibrillation treated with dabigatran etexilate, the level of adherence will be measured using a questionnaire, the Danish National Prescription Registry and pillcount and will be related to…
- Conditions
- Atrial Fibrillation, Medication Adherence, Blood Coagulation Tests, Anticoagulants; Circulating, Hemorrhagic Disorder
- Trial name
- ARCADE (NCT03280368)
- Testing
- Bloodtest, Questionnaires
- Where
- Denmark
- Volunteers
- 430 people, healthy volunteers welcome
- Sponsor
- Hospitalsenheden Vest
Atrial Fibrillation
Patients' Assessment of Satisfaction for Stroke Prevention in Atrial Fibrillation
To describe the treatment perception from patients with non-valvular atrial fibrillation (NVAF) receiving Pradaxa® or VKA for stroke prevention by using the self-estimation questionnaire of PACT-Q during a 6-month study period.
- Trial name
- NCT03187197
- Testing
- Pradaxa®
- Where
- 24 sites in Taiwan
- Volunteers
- 1,315 people
- Sponsor
- Boehringer Ingelheim
Pneumonia, Viral
Steroid and Anticoagulant Therapy in covid19
As COVID-19 has neither standard treatment protocol nor guidelines, there are many treatment protocols foranti-inflammatory corticosteroids and anti-coagulations for severe COVID-19 pneumonia patients.
- Trial name
- SARS-CoV-2 (NCT05021588)
- Testing
- steroid and anticoagulants according to different protocols.
- Where
- Egypt
- Volunteers
- 123 people
- Sponsor
- Assiut University
Nonvalvular Atrial Fibrillation
The Adherence to Oral Anticoagulant in Chinese Patients With NVAF
Investigate the compliance of oral anticoagulants in Chinese NVAF patients and find out the causes, so as to provide basis for formulating effective measures to improve the compliance of oral anticoagulants.
- Trial name
- NVAF (NCT04942873)
- Testing
- adherence
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
High Risk Pregnancy, Pregnancy Complications
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
This treatment trial evaluates the addition of an anti-tumor necrosis factor-alpha drug, certolizumab, to usual treatment (a heparin agent and low-dose aspirin) in pregnant women with antiphospholipid syndrome (APS) and…
- Conditions
- High Risk Pregnancy, Pregnancy Complications, Antiphospholipid Syndrome in Pregnancy, Lupus Anticoagulant Disorder
- Trial name
- NCT03152058
- Testing
- Certolizumab Pegol
- Where
- 3 sites in United States, Canada
- Volunteers
- 55 people
- Sponsor
- David Ware Branch
Cirrhosis, Portal Vein Thrombosis
Safety of Anticoagulant Therapy After Endoscopic Treatment
The investigators aimed to verify the efficacy and safety of nadroparin calcium warfarin sequential (NWS) anticoagulation therapy after endoscopic therapy in PVT patients with cirrhosis and AVB.
- Conditions
- Cirrhosis, Portal Vein Thrombosis, Esophageal and Gastric Varices, Anticoagulant-induced Bleeding
- Trial name
- NCT04976543
- Testing
- nadroparin calcium-warfarin sequential anticoagulation
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Qilu Hospital of Shandong University
Therapeutic Plasma Exchange, Anticoagulant Therapy
Evaluation of Complication Rates Using Filter vs. Centrifuge and Heparin vs. Citrate Anticoagulation
Despite its growing use across the world, and similar efficacy, filter-based therapeutic plasma exchange (TPE) continues to be used less often that centrifuge-based TPE.
- Trial name
- NCT04351438
- Testing
- Active Comparator: centrifuge TPE with citrate, Active Comparator: Filter TPE with heparin, Active comparator: Filter TPE with citrate
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- University of Alabama at Birmingham
Percutaneous Coronary Intervention
Registry of the Combination of Antiplatelet Agents and Anticoagulant in Atrial Fibrillation Patients With a CHA2DS2VASc Score >1 Undergoing Percutaneous Coronary Interventions
Patients undergoing percutaneous coronary intervention (PCI) with stent implantation and requiring chronic anticoagulation for atrial fibrillation (AF) with a CHA2DS2-VASc >1 are required to receive triple antithrombotic therapy…
- Trial name
- NCT03012906
- Testing
- the prevalence of ischemic events
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Severe Preeclampsia, Antiphospholipid Syndrome
Antiphospholipid Antibodies and Early Severe Preeclampsia.
The Antiphospholipid Syndrome is an immune disease where the presence of antibodies directed against cell membrane phospholipids (antiphospholipid antibodies) can cause an hypercoagulable state that causes thrombosis and…
- Trial name
- NCT01538121
- Where
- Panama
- Volunteers
- 310 people
- Sponsor
- Saint Thomas Hospital, Panama
Non-valvular Atrial Fibrillation
Exploratory Observation of Two Short-term Regimens After LAA Occlusion by LAMax LAAC® Device for Subjects With Non-valvular Atrial Fibrillation
This is a prospective, single-center, randomized, exploratory clinical observation to explore the overall benefit of short-term dual antiplatelet or novel oral anticoagulant regimens after left atrial appendage (LAA) occlusion by…
- Trial name
- NCT05761704
- Testing
- Dual antiplatelet, Novel oral anticoagulant
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Venous Thromboembolism
Shared Decision-making Process for Unprovoked vEnous THromboEmbolism Management. (ETHER )
Venous thromboembolism (VTE) including deep vein thrombosis (DVT) and pulmonary embolism (PE) is a frequent disease and the third most common cause of cardiovascular death in the world after myocardial infarction and stroke.
- Trial name
- ETHER (NCT06731244)
- Testing
- Usual Care Group, shared decision-making process
- Where
- 20 sites in France
- Volunteers
- 2,400 people
- Sponsor
- University Hospital, Brest
Antithrombotic Agents Management
Management of Anticoagulant Therapy in Non-cardiac Surgery.
The perioperative treatment of patients receiving long-term anticoagulant therapy is challenging. This is attributed to the continuation of anticoagulants perioperatively, which is associated with an increased bleeding risk while…
- Trial name
- NCT04766606
- Where
- Greece
- Volunteers
- 614 people, healthy volunteers welcome
- Sponsor
- University of Ioannina
Pulmonary Embolism, Venous Thromboembolism
Implementing Prescriber-Pharmacist Collaborative Care for Evidence-based Anticoagulant Use
The researchers hypothesize that existing-prescription notifications directed to pharmacists are more likely to lead to a prescription change than existing-prescription notifications directed to prescribers.
- Conditions
- Pulmonary Embolism, Venous Thromboembolism, Atrial Fibrillation
- Trial name
- NCT05351749
- Testing
- New-prescription Alert, New-prescription Alert with referral option, Existing-prescription notification to prescriber
- Where
- United States
- Volunteers
- 306 people
- Sponsor
- University of Michigan
Atrial Fibrillation, Anticoagulants
Clinical Decision Support Tool for Improving the Adequacy of Anticoagulant Therapy in Non-valvular Atrial Fibrillation
Atrial fibrillation (AF) is the most common cardiac arrhythmia and increases the risk of ischemic stroke 4-5-fold. The prevention of complications is based on oral or antiplatelet anticoagulant treatment.
- Conditions
- Atrial Fibrillation, Anticoagulants, Clinical Decision Support Systems
- Trial name
- NACOs (NCT03367325)
- Testing
- CDS-NVAF
- Where
- Spain
- Volunteers
- 63,001 people
- Sponsor
- Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina